Ariad snags 'breakthrough' status on 2nd try
This article was originally published in Scrip
Executive Summary
Unlucky the first time around in seeking the FDA's breakthrough therapy designation, Ariad Pharmaceuticals on 2 October revealed the second time proved positive for the company's investigational anaplastic lymphoma kinase positive (ALK+) metastatic non-small-cell lung cancer (NSCLC) drug AP26113.